1. Home
  2. RLMD vs NCL Comparison

RLMD vs NCL Comparison

Compare RLMD & NCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • NCL
  • Stock Information
  • Founded
  • RLMD 2004
  • NCL 2013
  • Country
  • RLMD United States
  • NCL United States
  • Employees
  • RLMD N/A
  • NCL N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • NCL
  • Sector
  • RLMD Health Care
  • NCL
  • Exchange
  • RLMD Nasdaq
  • NCL Nasdaq
  • Market Cap
  • RLMD 22.0M
  • NCL 21.7M
  • IPO Year
  • RLMD N/A
  • NCL 2023
  • Fundamental
  • Price
  • RLMD $0.83
  • NCL $0.26
  • Analyst Decision
  • RLMD Hold
  • NCL
  • Analyst Count
  • RLMD 4
  • NCL 0
  • Target Price
  • RLMD $4.25
  • NCL N/A
  • AVG Volume (30 Days)
  • RLMD 840.1K
  • NCL 14.2M
  • Earning Date
  • RLMD 05-12-2025
  • NCL 06-17-2025
  • Dividend Yield
  • RLMD N/A
  • NCL N/A
  • EPS Growth
  • RLMD N/A
  • NCL N/A
  • EPS
  • RLMD N/A
  • NCL N/A
  • Revenue
  • RLMD N/A
  • NCL $15,576,857.00
  • Revenue This Year
  • RLMD N/A
  • NCL N/A
  • Revenue Next Year
  • RLMD N/A
  • NCL N/A
  • P/E Ratio
  • RLMD N/A
  • NCL N/A
  • Revenue Growth
  • RLMD N/A
  • NCL 47.13
  • 52 Week Low
  • RLMD $0.24
  • NCL $0.15
  • 52 Week High
  • RLMD $4.47
  • NCL $1.52
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 72.41
  • NCL 37.43
  • Support Level
  • RLMD $0.65
  • NCL $0.77
  • Resistance Level
  • RLMD $0.77
  • NCL $1.52
  • Average True Range (ATR)
  • RLMD 0.10
  • NCL 0.26
  • MACD
  • RLMD 0.02
  • NCL -0.02
  • Stochastic Oscillator
  • RLMD 86.00
  • NCL 6.55

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About NCL Northann Corp.

Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe.

Share on Social Networks: